RxDoctor Payments DataLook up a doctor →

Laila Tabatabai, MD

Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1477788214

Payments from drug & device makers

$780,477in general payments, 2019–2025

Across 540 payments — averaging $1445.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kyowa Kirin, Inc.$395K
  • Ultragenyx Pharmaceutical Inc.$243K
  • Amgen$96K
  • Radius Health, Inc.$45K
  • Abbott$359
  • Lilly USA, LLC$276
  • plus $836 from 12 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$780,477 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas

Medicare billing

Part B allowed, 2024
$1,123,652
Medicare patients
1,336
Services billed
65,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →